Barriers to overcome for transition of breath tests from research to routine clinical practice

Journal of Breath Research

Volumn 5, Issue 3, 2011, Pages

  Modak, Anil S ^a  

^a CAMBRIDGE ISOTOPE LABORATORIES INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON DIOXIDE;

BREATH ANALYSIS; CLINICAL PRACTICE; FINANCIAL MANAGEMENT; HUMAN; LIQUID PHASE MICROEXTRACTION; MARKETING; MASS FRAGMENTOGRAPHY; MASS SPECTROMETER; MASS SPECTROMETRY; MEDICAL INSTRUMENTATION; MEDICAL RESEARCH; PRIORITY JOURNAL; REVIEW; EDITORIAL; EXHALATION; LUNG DISEASE; METABOLISM; METHODOLOGY; UNITED STATES;

BIOMEDICAL RESEARCH; BREATH TESTS; CARBON DIOXIDE; EXHALATION; HUMANS; LUNG DISEASES; UNITED STATES;

EID: 80052766082     PISSN: 17527155     EISSN: 17527163     Source Type: Journal    
DOI: 10.1088/1752-7155/5/3/030202     Document Type: Review

References (24)

1. Pauling L, Robinson A B, Teranishi R and Cary P 1971 Quantitative analysis of urine vapor and breath by gas-liquid partition chromatography Proc. Natl Acad. Sci. USA 68 2374-84
2. Phillips N, Herrera J, Krishnan S, Zain M, Greenberg J and Cataneo R 1999 Variation in volatile organic compounds in the breath of normal humans J. Chromatogr. B 729 75-88 (Pubitemid 29264111)
3. Jansson B O and Larsson B T J 1969 Analysis of organic compounds in human breath by gas chromatography-mass spectrometry laboratory J. Lab. Clin. Med. 74 961-6
4. Modak A 2007 Stable isotope breath tests in clinical medicine: a review J. Breath Res. 1 014003
5. Phillips M et al 1999 Volatile organic compounds in breath as markers of lung cancer: across-sectional study Lancet 353 1930-3 (Pubitemid 29255706)
6. Phillips M et al 2003 Detection of lung cancer with volatile markers in the breath Chest 123 2115-23 (Pubitemid 36706741)
7. Phillips M et al 2007 Prediction of lung cancer using volatile biomarkers in breath Cancer Biomark. 3 (2) 95-109 (Pubitemid 47103811)
8. Phillips M et al 2006 Prediction of breast cancer using volatile biomarkers in the breath Breast Cancer Res. Treat. 99 19-21 (Pubitemid 44168599)
9. Phillips M et al 2007 Volatile biomarkers of pulmonary tuberculosis in the breath Tubercul. (Edinb.) 87 44-52 (Pubitemid 44960164)
10. Phillips M et al 2004 Heart allograft rejection: detection with breath alkanes in low levels (the HARDBALL study) J. Heart Lung Transpl. 23 701-8 (Pubitemid 38721439)
11. Modak AS 2009 13C breath tests in personalized medicine: fiction or reality? Exp. Rev. Mol. Diagnos. 9 805-15
12. Ben-Oren I, Carlebach E, Daich J, Colman L, Levitsky G, Givron B and Katzman D 2003 Breath test apparatus and methods US Patent 6656127
13. Fabinski W, Wiegleb G, Hering P, Fuss W and Haisch M 1996 Non-dispersive infrared spectrometer US Patent 5486699
14. Opekun A, Abdalla N, Sutton F, Hammoud F, Kuo G, Torres E, Steinbauer J, Graham D and Tsuchiya K 2005 Improved infrared spectrophotometer for point-of-care patient [13]C-urea breath testing in the primary care setting Clin. Biochem. 38 731-4
15. Ulanowska A, Ligor T, Michel M and Buszewski B 2010 Hyphenated and unconventional methods for searching volatile cancer biomarkers Ecol. Chem. Eng. 17 (1) 9-22
16. Martin A N, Farquar G R, Jones A D and Frank M 2009 Human breath analysis: methods for sample collection and reduction of localized background effects Anal. Bioanal. Chem. 396 739-50
17. Modak A S 2010 Single time point diagnostic breath tests: a review J. Breath Res. 4 017002
18. Smith D, Spanel P and Sule-Suso J 2010 Advantages of breath testing for the early diagnosis of lung cancer Expert Rev. Mol. Diagn. 10 255-7
19. Modak A S 2010 Breath biomarkers for personalized medicine Personal. Med. 7 643-53
20. Gutman S and Hackett J 2006 Search for shortcuts on the critical path to market: US FDA perspectives from the diagnostic side Pharmacogenomics 7 1223-7
21. Hinman L, Spear B, Tsuchihashi Z, Kelly J, Bross P, Goodsaid F and Kalush F 2009 Drug-diagnostic codevelopment strategies: FDA and industry dialog 4th FDA/DIA/PhRMA/PWG/BIO Pharmacogenomics Workshop Pharmacogenomics 10 (1) 127-36
22. Drug-diagnostic co-development concept paper www.fda.gov/downloads/Drugs/ ScienceResearch/ResearchAreas/Pharmacogenetics/UCM116689.pdf
23. Težak Z, Kondratovich M V and Mansfield E 2010 US FDA and personalized medicine: in vitro diagnostic regulatory perspective Personal. Med. 7 517-30
24. Philip R, Carrington L and Chan M 2011 US FDA perspective on challenges in co-developing in vitro companion diagnostics and targeted cancer therapeutics Bioanalysis 3 383-9